Transforming drug discovery
The Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium is a public-private partnership with the mission of transforming drug discovery by accelerating the development of more effective therapies for patients.
In June 2016, GSK, the Department of Energy, and the National Cancer Institute announced their intent to create the ATOM partnership as one of the Cancer Moonshot task forces, with funding support under the 21st Century Cures Act.
The ATOM Consortium was officially established in October 2017.
ATOM founding members are GSK, Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, and the University of California, San Francisco.
Our goal is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and patient-centric model. We are integrating high performance computing, diverse biological data, and emerging biotechnologies to create a new pre-competitive platform for drug discovery.